Companies / JointMedica

Medical device company profile

JointMedica

Hip arthroplasty developer advancing metal-on-polyethylene hip resurfacing through the Polymotion clinical program.

Medical Device DeveloperOrthopedics & MusculoskeletalJoint ReconstructionClinical development

Headquarters🇬🇧Hallow, Worcestershire, United Kingdom

FoundedNot confirmed

Commercial statusIn developmentPolymotion is investigational in the United States; non-U.S. procedures are reported but market-by-market authorization is not fully mapped.

EmployeesNot confirmed

Estimated revenueNot confirmed

Official websitewww.jointmedica.com ↗

Company overview

JointMedica develops hip arthroplasty technology from Worcestershire, UK. Its Polymotion Hip Resurfacing System combines a metal femoral cap with a polyethylene bearing and titanium-coated shell, pursuing a bone-conserving alternative to total hip replacement for selected patients.

The U.S. Polymotion program remains investigational. An IDE study and FDA Breakthrough Device designation support clinical development, but do not authorize routine U.S. sales. The company also reports procedures outside the U.S.; those reports do not establish authorization in every market.

President Sharat Kusuma leads a team spanning implant design, manufacturing and commercialization. The current product page identifies Advita Ortho as a distribution partner. Trial execution, longer-term outcomes and market-specific regulatory progress are central to the company’s commercialization story.

^{[10][11][13][14]}

Leadership

3 people

Sharat KusumaPresident ^[14]

Tim BandChief Commercial Officer ^[14]

Jeremy NelsonVice President of Research & Development ^[14]

Products & regulatory status How does MedTechIndex get this information?

Summary

Polymotion hip resurfacing remains investigational in the United States. The company reports full enrollment of 238 patients in its IDE study and entry into follow-up; this supersedes the older 60%-enrollment page. Study permission, Breakthrough designation and overseas procedures do not establish U.S. marketing approval. ^{[13][11][8][12][14][1]}

No matching FDA recall event was identified in the completed company/applicant, linked-identifier and product-name searches. ^[5][3]

Regulatory snapshot How to read this snapshot

U.S. FDA

0
510(k) clearances: 0
De Novo grants: 0
PMA approvals: 0
Recall events

Latest recorded source review: 2026-10-20.

Commercial portfolio snapshot

No routinely marketed devices established in the reviewed scope.

Commercial development

JointMedica reports full enrollment of 238 Polymotion IDE-study participants and the start of a planned two-year follow-up phase. Enrollment is a development milestone; no FDA decision date or U.S. launch date is established. ^{[12][14][11][13][10][9]}

Investigational hip resurfacing implant